Input 2021.01.26 15:48 | Revision 2021.01.26 16:31
Samsung Biologics announced on the 26th that its annual sales in 2020 were KRW 1.166.4 trillion and operating profit was KRW 292.8 billion. Since its foundation in April 2011, it has exceeded KRW 1 trillion in annual sales.
The company’s sales increased by 4632 billion won (66%) compared to the previous year due to the increase in the utilization rate of all plants in the 1st, 2nd and 3rd, and operating profit increased by 211 billion won (219.3%).
The operating margin has nearly doubled from 13% in 2019 to 25% in 2020 due to the effect of operating leverage.
The operating leverage effect refers to the effect of a larger increase in operating profit compared to the increase in sales when sales exceed a certain level in a business area where a large percentage of fixed costs are accounted for.
Samsung Biologics’ sales increased about 12 times in 2020 compared to 2015, when sales began to occur in earnest. The average annual sales growth rate for five years reached 66.4%.
Last year, Samsung Biologics won orders of $1.78 billion (approximately 1.89 trillion won), which is about 2.5 times the sales of 2019, including $627 million (approximately 690 billion won) with Glaxos Miss Kline (GSK), a British global pharmaceutical company. did.
An official from Samsung Biologics said, “This increase in sales was mainly due to the strengthening of company-wide order-taking capabilities through rapid response, such as supporting due diligence and inspection by global regulatory agencies through non-face-to-face real-time virtual tours even in a difficult environment caused by the Corona 19 pandemic.” “This year, we will focus on efficient operation of production facilities and early orders for the 4th plant.”
Sales in the fourth quarter achieved the highest quarterly performance ever. As the factory utilization rate improved and some COVID-19 treatments were reflected in sales, sales increased by 100.7 billion won (36.7%) to 375.3 billion won compared to the third quarter, and operating profit increased by 36.1 billion won (63.9%) to 96.2 billion won. did.
Samsung Biologics announced that it has received a total of 47 CMO (consigned production) orders so far at the’JP Morgan Healthcare Conference’ held online in January. This year, it announced that it will focus its capabilities on efficient operation of production facilities and early orders for the 4th plant. The company plans to secure next-generation growth engines and super-differential competitiveness by expanding production capacity and diversifying business portfolios within 10 years.
Samsung’s bio business is now on track. This year, through the expansion of the CMO business, they joined the ‘1 trillion sales club’. Samsung Electronics Vice Chairman Lee Jae-yong aims to develop into’New Samsung’ in August 2018, and selects artificial intelligence (AI), 5th generation mobile communication (5G), automobile electronic equipment, etc., including bio, among the four new listing engines and won 180 trillion won. It has disclosed an investment plan that reaches to. However, there is also a growing concern that the vice chairman’s legal restraint will put a brake on key new growth businesses such as bio.